[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624807":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":35,"collaborators":10,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":41,"sex":47,"minAge":48,"maxAge":10,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":63,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"University of Belgrade","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"HCC Patients Treated With TACE",null,"Patients with hepatocellular carcinoma (HCC) who are candidates for transarterial chemoembolization (TACE) as part of their standard clinical care. This group includes adult patients with preserved liver function (Child-Pugh ≤ 7) and good performance status Eastern Cooperative Oncology Group (ECOG) 0.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Marko Stojanović, Medical Doctor","CONTACT","+381601435353","marko.stojanovic@med.bg.ac.rs",[19],{"facility":20,"status":10,"city":21,"state":10,"zip":10,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"KBC Bežanijska kosa","Belgrade","Serbia","RS",{"type":25,"coordinates":26},"Point",[27,28],20.46513,44.80401,{"lat":28,"lon":27},[31],{"name":32,"role":15,"phone":33,"phoneExt":10,"email":34},"Jovana Popović, Medical Doctor","+38162214194","jovana.lalatovic@gmail.com",{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Marko Stojanovic","Associate Professor, Department of Pharmacology, Clinical Pharmacology and Toxicology","100624807","validation-of-blood-based-biomarkers-in-tace-treated-hepatocellular-carcinoma-100624807",false,"NCT07414433","Validation of Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma","Blood-Based Biomarkers for Prediction and Monitoring of Response to TACE in Hepatocellular Carcinoma","BLOOD-TACE-M","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Diagnosis of hepatocellular carcinoma (HCC) based on LI-RADS CT\u002FMRI v2018 criteria or histopathological verification\n* Candidate for TACE as part of standard treatment (BCLC criteria)\n* Child-Pugh score ≤ 7 at the time of TACE indication\n* ECOG performance status 0 at the time of TACE indication\n* Availability of at least one follow-up multiphase CT or MRI scan 4-8 weeks after TACE\n\nExclusion Criteria:\n\n* Child-Pugh score ≥8 at the time of TACE indication\n* Eastern Cooperative Oncology Group (ECOG) performance status \\> 0 at the time of TACE indication.\n* Presence of extrahepatic dissemination and\u002For macrovascular invasion\n* Technically unfeasible TACE (e.g., inability to identify feeder artery)\n* Severe uncorrectable coagulopathy or cytopenia\n* Severe allergy or contraindication to iodine contrast agent or drugs used during TACE\n* Pregnancy or breastfeeding\n* Inability to provide signed informed consent","ALL","18 Years",{"count":50,"type":51},60,"ESTIMATED","OBSERVATIONAL","The goal of this prospective observational study is to validate the clinical utility of specific blood-based biomarkers for predicting and monitoring treatment response in patients with hepatocellular carcinoma (HCC) undergoing Transarterial Chemoembolization (TACE).\n\nThe study aims to determine if longitudinal changes in these biomarkers can reliably correlate with early radiological treatment response, as measured by Modified Response Evaluation Criteria in Solid Tumors (mRECIST). Participants will receive standard-of-care TACE treatment and will provide blood samples at baseline and during subsequent clinical follow-up cycles. Biomarker levels will be compared against routine multiphase computed tomography (CT) or Magnetic Resonance Imaging (MRI) scans performed four to eight weeks post-procedure to establish their accuracy as predictive tools for clinical success.",[55,56],"Hepatocellular Carcinoma (HCC)","Liver Neoplasms",[58,59,60,61,62],"Hepatocellular Carcinoma","TACE","Biomarkers","mRECIST","Drug-Eluting Beads","NOT_YET_RECRUITING","2026-02-09",{"date":66,"type":67},"2026-02-17","ACTUAL",{"date":69,"type":51},"2026-03-01",{"date":71,"type":51},"2029-12-30",{"name":5,"class":6},1]